Biomarkers driven treatment of selected NSCLC: ALK EML4 - Crizotinib - Crizotinib resistance - 2nd generation drugs

Date 08 July 2015
Event ESMO Preceptorship on NSCLC 2015
Session Session 4 - Biomarker driven treatment
Topics Anti-Cancer Agents & Biologic Therapy
Biomarkers
Non-Small-Cell Lung Cancer, Metastatic
Presenter Enriqueta Felip
Authors E. Felip
  • NA - NA/ES